OpGen Inc. (OPGN)
1.00
0.20 (25.00%)
At close: Jan 14, 2025, 11:29 AM
1.85
85.00%
After-hours Aug 19, 2024, 07:54 PM EDT
undefined% (undefined)
| Bid | 1.85 |
| Market Cap | 10.07M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -36.95 |
| PE Ratio (ttm) | -0.03 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 1.86 |
| Volume | 1,053 |
| Avg. Volume (20D) | 4,893 |
| Open | 0.90 |
| Previous Close | 0.80 |
| Day's Range | 0.90 - 1.00 |
| 52-Week Range | 0.53 - 9.90 |
| Beta | undefined |
About OPGN
OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis...
Industry Medical - Diagnostics & Research
Sector Healthcare
IPO Date May 5, 2015
Employees 85
Stock Exchange NASDAQ
Ticker Symbol OPGN
Website https://www.opgen.com
Analyst Forecast
According to 1 analyst ratings, the average rating for OPGN stock is "Hold." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.
Buy 0.00%
Hold 100.00%
Sell 0.00%
9 months ago ·
Source
-4.27%
OpGen shares are trading lower as the stock pulls ...
Unlock content with
Pro Subscription
9 months ago ·
Source
+57.89%
OpGen shares are trading higher after the company announced David Lazar will invest $3 million in preferred stock and take over as CEO.
